相关实验视频

Updated: Jun 28, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

综合药物分析和CRISPR查确定了慢性髓性白血病中的BCR::ABL1独立漏洞

Shady Adnan Awad¹, Olli Dufva², Jay Klievink³

¹Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, 00290 Helsinki, Finland; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, 00014 Helsinki, Finland; Foundation for the Finnish Cancer Institute, 00290 Helsinki, Finland; Clinical Pathology Department, National Cancer Institute, Cairo University, 11796 Cairo, Egypt.

Cell reports. Medicine

|April 23, 2024

概括

针对Wee1,MDM2和BCL2的新药对慢性髓性白血病 (CML) 干细胞显示出希望. 将它们与氨酸激酶抑制剂 (TKI) 结合起来,可以克服TKI初级耐药性,为CML提供新的治疗策略.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

慢性髓性白血病 (CML) 中对氨酸激酶抑制剂 (TKIs) 的初级耐药性通常是由BCR::ABL1-独立的途径驱动的.
这些途径有助于白血病干细胞的持久性,阻碍了疾病的完全根除.

研究的目的:

确定新的治疗点和药物组合,以克服CML中初级TKI耐药性.
调查TKI耐药性背后的机制以及非BCR::ABL1向剂的疗效.

主要方法:

使用单一药物和TKI组合进行CMLCD34+白血病干细胞/原生细胞的ex vivo药物查.
基于流细胞计的药物查,以评估细胞分化.
全基因组的CRISPR-Cas9查以确定耐药性基因.

主要成果:

对Wee1,MDM2和BCL2抑制剂的敏感性被确定,这些抑制剂有效地抑制了原始的CD34+CD38-CML细胞,并与TKI协同作用.
确定美巴克林可诱导CD34+CD38-细胞的分化.
克里斯普尔-卡斯9查揭示了调解者复合物,细胞亡和红色腺体系基因作为关键的TKI耐药性因素,对Wee1抑制剂AZD1775和美巴克林具有不同的耐药性.
鉴定出KCTD5是一种TKI抗性基因,介导BCR::ABL1无处不在.

结论:

描述了导致CML中初级TKI耐药性的机制.
识别非BCR::ABL1向药物和可能优化CML治疗策略的组合.
洞察白血病干细胞的持久性和潜在的治疗漏洞.

关键词:

BCR::ABL1独立的电阻在CML中,CML是CML.通过CRISPR-Cas9查进行查.KCTD5KCTD5 KCTD5 KCTD5 KCTD5 KCTD5 KCTD5 KCTD5 KCTD5 这里是TKI TKI.药物组合是药物组合.药物重用是为了改变药物的用途.药物查对药物进行查.原始人的祖先.干细胞是一种干细胞.

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...